课题基金 / 基金详情

Novel clinical trial designs for establishing potential efficacy of complex interventions

Novel clinical trial designs for establishing potential efficacy of complex interventions
用于确定复杂干预措施潜在功效的新颖临床试验设计
批准号:
MR/N015444/1
负责人:
Duncan Wilson
金额:
$31.94万
依托单位:
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
获得一种新疗法是否比目前可用的疗法更好的证据是困难、耗时和昂贵的。理想情况下,它需要一个包括数百名甚至数千名患者在内的大型实验。为了确保只有那些有很大机会发现有益效果的治疗方法才会进行这些昂贵的实验,通常首先进行较小的“探索性”实验,给出治疗是否值得进一步研究的初步迹象。当治疗方法是药物时,这些探索性实验是常见的,但并不是所有的治疗方法都是药物。一个例子是心理学家为抑郁症患者提供的心理治疗。另一个例子可能是像匿名酗酒者这样的支持团体。其他非药物治疗(称为“复合干预”)可以包括手术、物理治疗、职业治疗、语言治疗或护理。测试这些复杂的干预措施通常比测试药物更难。这在一定程度上是因为我们经常对治疗影响患者的多种方式感兴趣,而不是专注于单一的衡量标准。另一个并发症来自于很难弄清楚是什么产生了效果--治疗本身,还是提供治疗的人。当设计探索性实验来检查复杂的干预措施时,一个根本的决定是要研究多少患者和护理人员。这一点很重要,因为它将决定研究人员对实验结果的信心程度。实验规模越大,我们就越不可能仅凭偶然的机会观察到治疗的极端效果。然而,我们也希望保持尽可能小的实验,以最大限度地减少成本和参与者的时间。因此,统计学家需要计算出最小的参与者数量,这将使研究界对结果有足够的信心,从而使研究资助者能够就采用哪些治疗方法进行大型、昂贵的实验做出可靠的决定。然而,用于复杂干预的探索性实验的方法还没有开发出来。在这个项目中,我将开发这些方法,使研究人员能够正确地设计探索性实验,以可靠和有效的方式测试复杂的干预。我将开发这些方法的几个变体,以便它们可以在一系列情况下应用。我将从扩展药物开发中使用的现有方法开始,专注于将做出错误决定的可能性保持在较低水平(例如,对大型昂贵的实验进行无效的治疗)。在此之后,我将考虑如何利用现有的有关治疗的信息,例如我们预计其效果在人群中会有多大差异,这将有助于将所需的参与者数量降至最低。最后,我将开发明确考虑决策后果的方法,导致更好地反映所有感兴趣各方的优先事项的实验。所有这些方法都将是计算机密集型的。为了帮助其他人使用它们,我还将花费时间编写用户友好和高效的计算机软件,使它们能够快速和轻松地使用,并将这些方法应用于试验设计问题的真实例子。这将涉及与临床医生和其他统计学家的合作,并将有助于确保所开发的方法易于应用并将在实践中使用。开发这些方法将改进开发和测试复杂干预措施的过程。他们将确保可用于进行大型临床试验的有限资源(包括研究资金和参与者时间)明智地用于显示最有希望的治疗方法。反过来,这将提高识别和提供新干预措施的速度,提高整个NHS范围内患者的护理标准。
英文摘要
Obtaining evidence about whether or not a new treatment is better than currently available treatments is difficult, time-consuming and expensive. Ideally, it requires a large experiment including hundreds, or even thousands, of patients. To make sure only treatments which have a good chance of being found to have a beneficial effect undergo these expensive experiments, smaller 'exploratory' experiments are often carried out first, giving an initial indication of whether the treatment is worth studying further.When the treatment is a drug, these exploratory experiments are common, but not all treatments are drugs. One example would be a psychotherapy treatment delivered by a psychologist for patients suffering depression. Another example might be a support group like alcoholics anonymous. Other non-drug treatments (known as 'complex interventions') can include surgery, physiotherapy, occupational therapy, speech therapy or nursing. It is generally more difficult to test these complex interventions than drugs. This is partly because we are often interested in a number of ways in which the treatment affects patients, as opposed to focussing on a single measure. Another complication comes from it being difficult to work out what is having the effect - the treatment itself, or the person delivering the treatment. When designing exploratory experiments to examine complex interventions, a fundamental decision is how many patients and care providers to study. This is important because it will determine how confident researchers can be in the results of the experiment. The larger the experiment, the less likely that we will observe an extreme effect of the treatment by chance alone. However, we also want to keep experiments as small as possible to minimise the cost and participant's time. Statisticians therefore need to work out the smallest number of participants which will give the research community enough confidence in the results to allow research funders to make reliable decisions about which treatments to take on to large, expensive experiments. However, methods for doing this for exploratory experiments of complex interventions have yet to be developed.In this project I will develop these methods, enabling researchers to properly design exploratory experiments testing complex interventions in a reliable and efficient way. I will develop several variants of the methods so that they can be applied in a range of situations. I will start by extending existing methods used within drug development, focusing on keeping the chance of making an incorrect decision (e.g. taking an ineffective treatment on to a large expensive experiment) low. After this, I will consider ways to use existing information about the treatment, such as how much we expect its effect to vary among the population, which will help minimise the number of participants needed. Finally, I will develop methods that explicitly consider the consequences of decisions, leading to experiments which better reflect the priorities of all interested parties.All of these approaches will be computer intensive. To help others use them, I will also spend time writing user-friendly and efficient computer software which allows them to be used quickly and easily and will apply the methods to real examples of trial design problems. This will involve working with clinicians and other statisticians, and will help to make sure that the methods developed are easy to apply and will be used in practice.Developing these methods will improve the process of developing and testing complex interventions. They will ensure that the limited resources available for running large clinical trials (including research funds and participant time) are spent wisely on the treatments which show the most promise. In turn, this will increase the rate at which new interventions are identified and made available, improving the standard of care for patients across the breadth of the NHS.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
A hypothesis test of feasibility for external pilot trials assessing recruitment, follow-up, and adherence rates.
评估招募、随访和依从率的外部试点试验可行性的假设检验。
DOI: 10.1002/sim.9091
发表时间: 2021
期刊: Statistics in medicine
影响因子: 2
作者: [Wilson DT]
通讯作者: Wilson DT
DOI: 10.1002/sim.8941
发表时间: 2021-05-30
期刊: Statistics in medicine
影响因子: 2
作者: [Wilson DT, Wason JMS, Brown J, Farrin AJ, Walwyn REA]
通讯作者: Walwyn REA
国内基金
海外基金
"胚胎/生殖细胞发育特性激活”促进“神经胶质瘤恶变”的机制及其临床价值研究
  • 批准号:
    82372327
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    马展
  • 依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
  • 批准号:
    82372328
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    项盈
  • 依托单位:
自身免疫性T细胞的抗原决定簇在抗肾小球基底膜病发病中的启动机制
  • 批准号:
    81170645
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2011
  • 负责人:
    崔昭
  • 依托单位:
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data